Harrow’s (HROW) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Harrow (NASDAQ:HROW) in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a $57.00 target price on the stock.

Separately, B. Riley cut their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th.

Harrow Stock Performance

NASDAQ HROW opened at $26.05 on Monday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow has a fifty-two week low of $9.86 and a fifty-two week high of $59.23. The business has a fifty day moving average of $28.36 and a 200-day moving average of $37.63. The stock has a market cap of $927.77 million, a price-to-earnings ratio of -27.71 and a beta of 0.69.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million. As a group, analysts predict that Harrow will post -0.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Harrow

Several hedge funds and other institutional investors have recently made changes to their positions in HROW. Braidwell LP boosted its position in Harrow by 106.3% in the 4th quarter. Braidwell LP now owns 907,039 shares of the company’s stock valued at $30,431,000 after buying an additional 467,401 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after buying an additional 194,480 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Harrow by 195.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock worth $11,313,000 after acquiring an additional 166,602 shares during the period. Two Sigma Investments LP grew its holdings in shares of Harrow by 483.2% during the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock valued at $5,044,000 after purchasing an additional 124,574 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in shares of Harrow by 128.0% during the 4th quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company’s stock worth $6,728,000 after purchasing an additional 112,588 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.